{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:38:50Z","timestamp":1758587930257,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.therap.2022.01.017","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T19:42:45Z","timestamp":1643744565000},"page":"523-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing real-life carbamazepine exposure between innovator and generic formulation"],"prefix":"10.1016","volume":"77","author":[{"given":"Emna","family":"Ga\u00efes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Jebabli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Zerei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Charfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Salouage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Ben Sassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanene","family":"El Jebari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riadh","family":"Daghfous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.01.017_bib0030","first-page":"S1","article-title":"Statistical issues in bioavailability\/bioequivalence studies","volume":"40","author":"Shein-Chung","year":"2011","journal-title":"J Bioequiv"},{"key":"10.1016\/j.therap.2022.01.017_bib0035","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2022.01.017_bib0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5639\/gabij.2015.0404.035","article-title":"Bioequivalence of narrow therapeutic index drugs and immunosuppressives","volume":"4","author":"Baumg\u00e4rtel","year":"2015","journal-title":"Generics and Biosimilars Initiative Journal"},{"key":"10.1016\/j.therap.2022.01.017_bib0045","first-page":"572","article-title":"Comparison of salivary versus serum carbamazepine and phenytoin levels in epileptic children","volume":"50","author":"Siraslewala","year":"2008","journal-title":"Bombay Hospital Journal"},{"key":"10.1016\/j.therap.2022.01.017_bib0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin Neuropharmacol."}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:40Z","timestamp":1758567280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722000282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0040595722000282"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.01.017","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing real-life carbamazepine exposure between innovator and generic formulation","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}